Q1 2024 Earnings Summary
- Strong growth in Immunodiagnostics business with high expectations for the full year: Revvity's Immunodiagnostics segment had a solid first quarter and is expected to grow in the high single digits for the full year, driven by geographic expansion and new product launches. The U.S. market is a particularly strong growth driver.
- Positive outlook for Signals Software business with new SaaS offerings and strong customer response: The Signals Software division launched several new SaaS-based products and expects to grow at high single-digit to low-double-digit annual rates, reflecting strong customer demand and significant market potential.
- Encouraging trends in pharma/biotech customer engagement, potentially leading to future order growth: Recent conversations with pharma and biotech customers are becoming more solid and prolonged, an encouraging trend that may lead to future order growth in Revvity's Life Sciences instruments segment.
- Persistent Pricing Headwinds in China: The company is facing consistent pricing pressures in China throughout the year, which could impact revenue growth in this key market.
- Delayed Recovery in Pharma/Biotech Orders: Despite more constructive conversations with pharma and biotech customers, Revvity has not yet seen a meaningful improvement in order rates, especially in high-ticket instrumentation, indicating continued weakness in this segment.
- Unresolved Litigation Impacting Operations: Operational disruptions caused by litigation related to Spotfire in March could pose ongoing risks, despite an injunction being received to maintain the status quo.
-
Reagents Business Outlook
Q: When will the reagents business recover?
A: Management expects the core reagents business to return to growth, anticipating mid-single-digit increases for the full year. After a slow start due to delayed customer budgets, trends in March and April have been encouraging, supporting confidence in their outlook. -
Operating Margin Expansion
Q: How confident are you in improving operating margins?
A: Operating expenses are expected to remain flat, with gross margins improving throughout the year due to higher volumes. Management is confident in achieving a 28% operating margin for the full year, anticipating an increase to around 31% in the fourth quarter as volumes ramp up. -
Instrument Demand Trends
Q: What is the outlook for instrument demand?
A: Instrumentation revenue is projected to decline mid- to high-single digits for the full year. While the first quarter performed better than expected, the company is not assuming a market recovery but rather a steady-state environment moving forward. -
China Performance and Expectations
Q: How is China impacting your business?
A: China's revenues are expected to be roughly flat for the full year. While there are ongoing pricing pressures due to VBP, the company anticipates improvements in the second half, especially in Reproductive Health, as the Year of the Dragon traditionally boosts birth rates. -
Software Business Growth
Q: How big can the software business get?
A: The software business is expected to grow at a high single-digit to low double-digit rate annually, currently at approximately $200 million. Recent product launches are directly addressing customer needs, expanding into clinical trials analytics, and are fully SaaS-based, providing longer-term revenue certainty. -
Applied Genomics Outlook
Q: What is the expectation for Applied Genomics?
A: Applied Genomics faced a decline of mid-20% in the first quarter but is expected to improve as the year progresses. The company anticipates a rebound, contributing to overall acceleration in Diagnostics in the second half. -
Acquisitions and Capital Allocation
Q: Would you have done acquisitions differently?
A: Management remains confident in their acquisition strategy focused on Life Sciences reagents related to biomolecules and cell and gene therapy. They believe these areas align with long-term industry trends, and despite current market headwinds, they are well-positioned for future growth. -
Immunodiagnostics Growth in the U.S.
Q: What's driving U.S. Immunodiagnostics growth?
A: The U.S. Immunodiagnostics business has grown at a 20% CAGR since acquisition, increasing from 5% to nearly 15% of the overall Immunodiagnostics revenue. Growth is driven by product expansion and obtaining FDA approvals, with significant potential remaining in the U.S. market. -
Cost Reduction Initiatives
Q: How will cost initiatives impact margins?
A: Structural cost reduction actions, particularly in SG&A, have been implemented and are factored into the 2024 plan. Long-term margin expansion efforts include in-sourcing, freight optimization, vendor consolidation, and facility consolidation, contributing to ongoing operating margin improvements. -
Automated Tuberculosis Testing Launch
Q: How does your new TB test compare to competitors?
A: The newly launched automated tuberculosis testing system reduces hands-on time by 50% and technician touchpoints by 80% compared to the existing T-SPOT Select. It offers less total hands-on time than competitor products by integrating specialized liquid handling and workflow optimizations.